TY - JOUR
T1 - Generation of a reporter yellow fever virus for high throughput antiviral assays
AU - Sanchez-Velazquez, Ricardo
AU - de Lorenzo, Giuditta
AU - Tandavanitj, Rapeepat
AU - Setthapramote, Chayanee
AU - Bredenbeek, Peter J.
AU - Bozzacco, Leonia
AU - MacDonald, Margaret R.
AU - Clark, Jordan J.
AU - Rice, Charles M.
AU - Patel, Arvind H.
AU - Kohl, Alain
AU - Varjak, Margus
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Yellow fever virus (YFV), a member of the Flaviviridae family, is an arthropod-borne virus that can cause severe disease in humans with a lethality rate of up to 60%. Since 2017, increases in YFV activity in areas of South America and Africa have been described. Although a vaccine is available, named strain 17D (Theiler and Smith, 1937), it is contraindicated for use in the elderly, expectant mothers, immunocompromised people, among others. To this day there is no antiviral treatment against YFV to reduce the severity of viral infection. Here, we used a circular polymerase extension reaction (CPER)-based reverse genetics approach to generate a full-length reporter virus (YFVhb) by introducing a small HiBit tag in the NS1 protein. The reporter virus replicates at a similar rate to the parental YFV in HuH-7 cells. Using YFVhb, we designed a high throughput antiviral screening luciferase-based assay to identify inhibitors that target any step of the viral replication cycle. We validated our assay by using a range of inhibitors including drugs, immune sera and neutralizing single chain variable fragments (scFv). In light of the recent upsurge in YFV and a potential spread of the virus, this assay is a further tool in the development of antiviral therapy against YFV.
AB - Yellow fever virus (YFV), a member of the Flaviviridae family, is an arthropod-borne virus that can cause severe disease in humans with a lethality rate of up to 60%. Since 2017, increases in YFV activity in areas of South America and Africa have been described. Although a vaccine is available, named strain 17D (Theiler and Smith, 1937), it is contraindicated for use in the elderly, expectant mothers, immunocompromised people, among others. To this day there is no antiviral treatment against YFV to reduce the severity of viral infection. Here, we used a circular polymerase extension reaction (CPER)-based reverse genetics approach to generate a full-length reporter virus (YFVhb) by introducing a small HiBit tag in the NS1 protein. The reporter virus replicates at a similar rate to the parental YFV in HuH-7 cells. Using YFVhb, we designed a high throughput antiviral screening luciferase-based assay to identify inhibitors that target any step of the viral replication cycle. We validated our assay by using a range of inhibitors including drugs, immune sera and neutralizing single chain variable fragments (scFv). In light of the recent upsurge in YFV and a potential spread of the virus, this assay is a further tool in the development of antiviral therapy against YFV.
KW - CPER
KW - Drug screen
KW - HiBiT
KW - Luciferase
KW - Yellow fever virus
U2 - 10.1016/j.antiviral.2020.104939
DO - 10.1016/j.antiviral.2020.104939
M3 - Article
SN - 0166-3542
VL - 183
JO - Antiviral Research
JF - Antiviral Research
M1 - 104939
ER -